One of the advantages of my strategy is that I always look for growth stocks with doubling potential before the broad market discovers them, even if this naturally entails a higher risk. I recently came across $ONWD (-1,49 %) recently. As it is a medtech company, it might also be interesting for the dear@Tenbagger2024 .

The neurotech company has three technology platforms with which it aims to give as many people as possible with restricted mobility a significantly better quality of life. The company's ARC-EX system is already approved in the USA (now also for home use) and Europe. Onward Medical is therefore entering the commercial phase. In the third quarter alone, the company sold 40 of these systems, which can now give people with spinal cord injuries a better quality of life.

While Onward Medical is making clear progress on the commercial side, the broad development pipeline is also being driven forward. Among other things, the company also wants to develop neurotech solutions for blood pressure management or Parkinson's disease. Apparently, the newcomer to the stock market Ottobock also finds the Onward Medical story appealing. As part of a capital measure in October, the prosthesis manufacturer once again invested money in the European neurotech hopeful. "The company's developments fit perfectly into our future strategy for neuroorthetics. We are therefore pleased to strengthen our role as the largest shareholder as well as our strategic partnership through our additional investment," says Ottobock CEO Oliver Jakobi.

After AI and quantum computing, neurotech could become the next megatrend on the stock market. In my opinion, Onward Medical has everything it takes to be valued significantly higher. On top of that, there is a shot of takeover fantasy.

I therefore think I will add a few shares to my portfolio.

$CRSP (-0,86 %) , $IOVA (-7,41 %) , $ABT (+0,28 %) & $ONWD (-1,49 %)

The healthcare and biotech sector remains one of the most exciting areas for long-term investors. Between pioneering gene editing, immunotherapies and neuronal interfaces, a new chapter in modern medicine is currently being written - with opportunities, but also considerable risk.

Here is a compact overview of four companies that play an interesting role in my view.

🧬 CRISPR Therapeutics ($CRSP (-0,86 %)
)

CRISPR Therapeutics is one of the absolute pioneers in the field of gene editing. The company uses the revolutionary CRISPR/Cas9 technologyto potentially cure genetic diseases permanently.

💡 Highlights:

• The first approved drug Casgevy (for sickle cell anemia and beta thalassemia) marks a historic success in gene therapy.
• Sales are currently still low, but the pipeline for rare diseases and oncology is strong.
• Analysts see medium-term price targets of $70 +depending on clinical progress.

Opportunity: If further indications become established, CRISPR could generate billions in sales in the long term.

⚠️ Risk: Research expensive, approvals complex, sales still in the start-up phase.

🧫 Iovance Biotherapeutics ($IOVA (-7,41 %)
)

Iovance develops TIL therapies (Tumor Infiltrating Lymphocytes) - immune cells that specifically target solid tumors. The concept is medically promising: letting the body heal itself with its own immune cells.

💡 Highlights:

• Initial approvals and encouraging clinical data are available.
• The share price has recently fluctuated significantly - typical for biotechs in the pre-revenue phase.

Opportunity: If commercialization is successful, $IOVA can scale strongly in the coming years.

⚠️ Risk: Capital-intensive and regulatory demanding - setbacks can hit hard.

🧠 Abbott Laboratories ($ABT (+0,28 %)
)

Abbott is an established player with a focus on medical technology, diagnostics and neurointerfaces. Particularly exciting: the neuromodulation divisionwhich uses electrical impulses to treat chronic pain or movement disorders.

💡 Highlights:

• Cooperation with the NIH BRAIN Initiative for the further development of neuroimplants.
• Stable sales, strong balance sheet and ongoing innovations in the area of biointerfaces and wearable MedTech solutions.

Opportunity: Demand for neuro and heart implants is growing in line with demographic change.

⚠️ Risk: Moderate growth rates, competition from Medtronic & Co.

🧬ONWARD Medical ($ONWD (-1,49 %)
)

ONWARD is one of the most exciting startups in the field of Neurotech & Brain-Computer-Interfaces (BCI). Their goal: to enable people with spinal cord injuries to move again - through direct neuronal communication between the brain and body.

💡 Highlights:

• Several FDA breakthrough designations for their implants.
• Initial clinical successes show that paraplegics can perform controlled movements again.

Opportunity: If the technology catches on, $ONWD could revolutionize rehab medicine.

⚠️ Risk: Very early stage, high research and approval costs, long time-to-market.

#stockanalysis
#biotech
#neurotech
#medizin
#healthcare
#medical

ONWARD Medical $ONWD (-1,49 %) has received approval from the U.S. Food and Drug Administration (FDA) for a pivotal clinical trial. The Empower BP trial will test the company's ARC-IM system, an implantable neurostimulation technology.

The goal of this technology is to treat blood pressure instability in people with spinal cord injury - a common and previously under-treated problem. The study will be conducted at around 20 research centers in the USA, Canada and Europe.

The first patients are expected to be enrolled in the study this year. The ARC-IM system is the first neuroprosthetic system developed specifically for this application and has been approved by the FDA as a "Breakthrough Device" by the FDA.

Shamelessly summarized by the AI, source: https://www.pharmiweb.com/article/onward-medical-receives-fda-ide-approval-to-initiate-the-empower-bp-pivotal-study-with-the-arc-im-sy (Original press release as PDF available at https://ir.onwd.com/static-files/273fa49c-4a2c-40d5-99f1-ff80bbd353da)

Today 720 $ONWD (-1,49 %) shares bought today. Let's see if I get rewarded.